Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2005-01-04
2005-01-04
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C264S004100, C264S004300, C264S004600
Reexamination Certificate
active
06838090
ABSTRACT:
The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.
REFERENCES:
patent: 4565806 (1986-01-01), Setälä
patent: 4684630 (1987-08-01), Repta et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4816247 (1989-03-01), Desai et al.
patent: 4826689 (1989-05-01), Violanto
patent: 4842856 (1989-06-01), Hoederath et al.
patent: 4997454 (1991-03-01), Violante et al.
patent: 5039527 (1991-08-01), Tabibi et al.
patent: 5077057 (1991-12-01), Szoka, Jr.
patent: 5091188 (1992-02-01), Haynes
patent: 5270053 (1993-12-01), Schneider et al.
patent: 5516770 (1996-05-01), Waranis et al.
patent: 5530006 (1996-06-01), Waranis et al.
patent: 5616330 (1997-04-01), Kaufman et al.
patent: 5616341 (1997-04-01), Mayer et al.
patent: 5616587 (1997-04-01), François et al.
patent: 5616588 (1997-04-01), Waranis et al.
patent: 5656296 (1997-08-01), Khan et al.
patent: 5672358 (1997-09-01), Tabibi et al.
patent: 5690954 (1997-11-01), Illum et al.
patent: 5714520 (1998-02-01), Jones et al.
patent: 5731356 (1998-03-01), Jones et al.
patent: 5736159 (1998-04-01), Chen et al.
patent: 893949 (1982-11-01), None
patent: 41 25 255 (1993-02-01), None
patent: 41 25 255 (1993-02-01), None
patent: 214501 (1987-03-01), None
patent: 215313 (1987-03-01), None
patent: 502766 (1992-09-01), None
patent: 0 648 494 (1995-04-01), None
patent: 0 720 853 (1996-07-01), None
patent: 770387 (1997-05-01), None
patent: 2 609 631 (1988-07-01), None
patent: WO 9853799 (1998-12-01), None
Eiseman et al., “#536 Pharmacokinetics of 17-allylamino(17demethoxy)geldanamycin in SCID mice bearing MDA-MB-453 xenografts and alterations in the expression of p185arb-B2in the xenografts following treatment”, AACR-NCI-EORTC International Conference, Nov. 16-19, 1999, Washington, DC.
Eiseman et al., “#2063 Plasma pharmacokinetics and tissue distribution of 17-allylaminogeldanamycin (NSC 330507), a prodrug for geldanamycin, in DC2F1mice and Fisher 344 rats”, Proceedings of the American Association for Cancer Research, vol. 38, Mar. 1998, p. 308.
Page et al., #2067 Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC0330507D) toxicity in rats, Proceedings of the American Association for Cancer Research, vol. 38, Mar. 1998, p. 308.
Egorin et al., “#3567 Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) (NSC 330507) by murine and human hepatic preparations”, Proceedings of the American Association for Cancer Research, vol. 38, Mar. 1998, p. 524.
Burger et al., “#504 Antitumor activity of 17-allylaminogeldanamycin (NSC 330507) in melanoma xanografts in associated with decline in Hsp90 protein expression”, 10thNCJ-EDRTC Symposium on New Drugs in Cancer Therapy, Jun. 16-19, 1999, Amsterdam.
Laurie McCarthy, “Nanonization” Technology Provides Solutions for the Insoluble, http:/
ews.pharmaceuticalonlin.com/feature-articles/19980113-72.html.
“KODAK Established Independent Business to Develop Small Particle Technology”, http://www.kodak.com/aboutKodak/corpInfo/pressReleases/pr951106-2.shtml.
“Nanoparticles”, Process and Characteristics, Formulations and Biodistribution, and Case Studies, http://www/stsduotek.com
anoport.htm © 1997-98.
Davis, “Biomedical applications of nanotechnology-implications for drug targeting and gen therapy”, Trends Biotechnol, Jun. 1997, 15(6):217-214 (Abstract only).
Sharma et al., “Novel taxol formulations: preparation and characterization of taxol-containing liposome”, Pharm Res, Jun. 1994, 11(6):889-896 (Abstract only).
Hauss et al., Lipid-based delivery systems for improving the ioavailability and lymphatic transport of a poorly water-woluble LTB4 inhibitor, J Pharm Sci, Feb. 1998, 87(2):164-169 (Abstract only).
Merisko-Liversidge et al., “Formulation and antitumor activity evaluation of nonocrystalline suspensions of poorly soluble anticancer drugs”, Parm Res, Feb. 1996, 13(2):272-278 (Abstract only).
Anderson et al., “Strategies in he design of solution-stable, water-soluble prodrugs II: properties of micellar prodrugs of methylprednisolone”, J Pharm Sci, Apr. 1985, 74(4):375-381 (Abstract only).
Storm et al., “Colloidal systems for tumor targeting”, Hybridoma, Feb. 1997, 16(1):119-125 (Abstract only).
Jones, “The surface properties of phospholipid liposome systems and their characterization”, Adv colloid Interface Sci, Jan. 3, 1995, 54:93-128 (Abstract only).
Storm et al., Biopharmaceutical aspects of lipid formulations of amphotericin B., Eur J Clin Microbiol Infect Dis, Jan. 1997, 16(1):64-73 (Abstract only).
Benita et al., “Submicron emulsions as colloidal drug carriers for Intravenous administration: comprehensive physicochemical characterization”, J Pharm Sci, Nov. 1993, 82(11):1069-1079 (Abstract only).
Gabizon, “Tailoring liposomes for cancer drug delivery: from the bench to the clinic”, Ann Biol Clin (Paris), 1993, 51(9):811-813 (Abstract only).
Marty et al., Nanoparticles—a new colloidal drug delivery system., Pharm Acta Helv, 1978, 53(1):17-23 (Title only).
Thompson, “Cyclodextrins—enabling excipients: Their present and future use in pharmaceuticals”, Critical Reviews in Therapeutic Drug Carrier Systems (USA), 1997, 14/1 (1-104) (Abstract only).
Sculier et al., “Intravenous Infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data”, J. Clin. Oncol. (USA), 1986, 4/5 (789-797), (Abstract only).
Torchilin et al., “Long acting thrombolytic immobilized enzymes”, J. Control. Release (Netherlands), 1985, vol. 2 (321-330) (Abstract only).
Laduron et al., “Chemotherapeutic efficacy of Nocodazole(Reg. Trademark) encapsulated in liposomes on L1210 murine leukemia”, Res. Commun. Chem. Pathol. Pharmacol. (USA), 1983, 39/3 (419-436) (Abstract only).
Alyautdin et al., “Delivery of loperamide across the blood-brain-barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles”, Pharmaceutical Research (New York) 14(3), 1997, 325-328 (Abstract only).
Leroux et al., “Pharmacokinetics of a novel HIV-1 protease inhibitor Incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice”, Journal of Pharmaceutical Sciences (J-Pharm-Sci) 84:1387-1391, Dec. 1995 (3 pages).
Page et al., “Comparison of geldanamycin (NSC0122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats”, Proc Annu Am Assoc Cancer Res, 38:A2067 1997 (Abstract only).
Eiseman et al., “Plasma pharmacokinetics and tissue distribution of 17-allylaminogeldanamycin (NSC-330507), a prodrug for geldanamycin, in DC2F1 mice and Fisher 344 rats”, Proc Annu Am Assoc Cancer Res, 38:A2063 1977 (Abstract only).
Larroque et al., “Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models”, Br J Cancer, 1996, 74(12):1886-90 (Abstract only).
Merisko-Liversidge et al., “Formulation and antitumor activity evaluationof nanocrystalline suspensions of poorly soluble anticancer drugs”, Pharm Res, 13(2):272-8 1996 (Abstract only).
Son, “Intravenous delivery of water-insoluble drugs”, Diss Absr Int [B], 52(5):2518 1991 (Abstract only).
Zuidam et al., “Sterilization of liposomes by heat treatment”, Pharm Res, 10(11):1591-6 1993 (Abstract only).
Tiurin-Kuz'Min et al., “Vliianie davleniia metabolicheski ine
Ezennia Emmanuel I.
Gupta Shanker
Tabibi S. Esmail
Vishnuvajjala B. Rao
Kishore Gollamudi S.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Water-insoluble drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water-insoluble drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water-insoluble drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3437586